bezafibrate has been researched along with Body Weight in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (16.13) | 18.7374 |
| 1990's | 9 (29.03) | 18.2507 |
| 2000's | 12 (38.71) | 29.6817 |
| 2010's | 5 (16.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, XY; Yang, YJ; Zhu, XH | 1 |
| Knapik-Czajka, M | 1 |
| Aguila, MB; Bargut, TC; de Carvalho, SN; Magliano, DC; Mandarim-de-Lacerda, CA; Souza-Mello, V | 1 |
| Aichler, M; Brachthäuser, L; Feuchtinger, A; Franko, A; Fuchs, H; Häring, HU; Hrabě de Angelis, M; Kovarova, M; Neff, F; Neschen, S; Peter, A; Rathkolb, B; Rozman, J; Wolf, E | 1 |
| Aoyama, T; Kojima, K; Murano, Y; Sekine, S; Takeuchi, H | 1 |
| Balasubramanian, R; Cobelli, C; Dalla Man, C; English, PT; Firbank, MJ; Gerrard, J; Lane, A; Taylor, R | 1 |
| Fujita, H; Hirose, H; Kawai, T; Miyashita, K; Ogawa, T; Saruta, T; Seto, Y; Ukeda, K; Yajima, K; Yamada, T; Yamamoto, Y | 1 |
| Narce, M; Poisson, JP | 1 |
| Jia, D; Otani, M; Otsuki, M; Yamamoto, M | 1 |
| Akahane, S; Matsuzawa, A; Mori, Y; Oana, F; Tajima, N; Tokutate, Y | 1 |
| Brand, CL; Pickavance, LC; Wassermann, K; Wilding, JP | 1 |
| Oron-Herman, M; Rosenthal, T; Sela, BA | 1 |
| Kohno, H; Sugie, S; Suzuki, R; Tanaka, T | 1 |
| Esmat, AY; Gawad, SM; Ibrahim, AM; Mohamed, MA; Refaie, FM | 1 |
| Harada, N; Kusuyama, A; Morishima, M; Nakaya, Y; Okada, K; Takahashi, A | 1 |
| Lang, PD; Vollmar, J | 1 |
| Boberg, J; Gustafsson, IB; Hellsing, K; Ledermann, H; Lithell, H; Ostlund-Lindqvist, AM; Vessby, B | 1 |
| Braeuning, C; Middelhoff, G; Schlierf, G; Wirth, A | 1 |
| Hofmann, H; Holler, HD; Stratmann, FW | 1 |
| Hausmann, L; Kaffarnik, H; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R | 1 |
| Bara, A; Chociłowska, D; Kozłowski, A; Okopień, B; Trzeciak, HI | 1 |
| Shand, JH; West, DW | 1 |
| Besnard, P; Carlier, H; Mallordy, A | 1 |
| Harada, Y; Inoue, I; Ishii, J; Itabashi, A; Katayama, S; Negishi, K; Takahashi, K | 1 |
| Auerbach, BJ; Barnett, BC; Bisgaier, CL; Bousley, R; Essenburg, AD; Kieft, KA; Krause, BR; Newton, RS; Stanfield, R | 1 |
| Båvenholm, P; de Faire, U; Ericsson, CG; Godsland, I; Hamsten, A; Jovinge, S; Nilsson, J; Proudler, A; Tornvall, P | 1 |
| Adzet, T; Alegret, M; Cabrero, A; Laguna, JC; Llaverías, G; Roglans, N; Sánchez, R; Vázquez, M | 1 |
| Richey, JM; Si, X; Webb, RC | 1 |
| Abdella, N; Akanji, AO; Mojiminiyi, OA | 1 |
| Adzet, T; Alegret, M; Cabrero, A; Laguna, JC; Rodríguez, C; Roglans, N; Sánchez, RM; Vázquez, M | 1 |
| Imanaka, T; Itoga, H; Okawa, S; Suga, T; Watanabe, T | 1 |
2 trial(s) available for bezafibrate and Body Weight
| Article | Year |
|---|---|
Treatment of familial hypercholesterolemia with a combination of bezafibrate and guar.
Topics: Adult; Apolipoproteins; Bezafibrate; Body Weight; Cholesterol; Cholesterol, LDL; Clofibrate; Clofibric Acid; Drug Therapy, Combination; Female; Galactans; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Mannans; Middle Aged; Plant Gums; Polysaccharides | 1982 |
Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease.
Topics: Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Coronary Artery Disease; Coronary Disease; Glucose; Homeostasis; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Risk Factors; Triglycerides; Tumor Necrosis Factor-alpha | 1998 |
29 other study(ies) available for bezafibrate and Body Weight
| Article | Year |
|---|---|
The effect of bezafibrate in preventing glucolipid abnormalities induced by the antipsychotic risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Bezafibrate; Blood Glucose; Body Weight; Drug Therapy, Combination; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Risperidone; Schizophrenia; Weight Gain; Young Adult | 2019 |
Stimulation of rat liver branched-chain alpha-keto acid dehydrogenase activity by low doses of bezafibrate.
Topics: 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide); Amino Acids, Branched-Chain; Animals; Bezafibrate; Body Weight; Dose-Response Relationship, Drug; Eating; Gene Expression Regulation, Enzymologic; Hypolipidemic Agents; Liver; Male; Organ Size; Phosphorylation; Random Allocation; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2013 |
Peroxisome proliferator-activated receptors-alpha and gamma are targets to treat offspring from maternal diet-induced obesity in mice.
Topics: Adipocytes; Adipose Tissue, White; Animals; Bezafibrate; Body Weight; Carbohydrate Metabolism; Cell Size; Diet, High-Fat; Drug Evaluation, Preclinical; Energy Intake; Energy Metabolism; Fatty Liver; Female; Gene Expression; Hypolipidemic Agents; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; PPAR alpha; PPAR gamma; Pregnancy; Pregnancy Complications; Prenatal Exposure Delayed Effects; Prenatal Nutritional Physiological Phenomena; Sterol Regulatory Element Binding Protein 1 | 2013 |
Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.
Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Experimental; Disease Models, Animal; Fatty Liver; Glucose; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Peroxisome Proliferator-Activated Receptors | 2017 |
Effect of dietary n-6/n-3 ratio on liver n-6/n-3 ratio and peroxisomal beta-oxidation activity in rats.
Topics: Animals; Bezafibrate; Body Weight; Dietary Fats; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Hypolipidemic Agents; Liver; Male; Organ Size; Oxidation-Reduction; Peroxisomes; Rats; Rats, Inbred BB | 2008 |
Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
Topics: Abdominal Muscles; Adult; Aged; Bezafibrate; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Liver; Middle Aged; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Triglycerides | 2010 |
Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice.
Topics: Animals; Bezafibrate; Body Weight; Diabetes Mellitus; Drug Therapy, Combination; Glucose; Glucose Transporter Type 2; Insulin; Insulin Secretion; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Monosaccharide Transport Proteins; Pancreas; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors | 2003 |
Novel PPARgamma-dependent and independent effects for thiazolidinediones.
Topics: Animals; Bezafibrate; Body Weight; Chromans; Diabetes Mellitus, Type 2; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Proteins; Mice; Monocytes; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Pregnancy Proteins; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone; Tumor Necrosis Factor-alpha | 2003 |
Bezafibrate on lipids and glucose metabolism in obese diabetic Otsuka Long-Evans Tokushima fatty rats.
Topics: Adipose Tissue; Animals; Bezafibrate; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Eating; Fatty Acids, Nonesterified; Glucose; Glucose Tolerance Test; Hypolipidemic Agents; Immunohistochemistry; Insulin; Insulin Resistance; Islets of Langerhans; Lipid Metabolism; Lipids; Obesity; Pancreas; Rats; Rats, Inbred OLETF; Triglycerides | 2004 |
Bezafibrate-induced changes over time in the expression of uncoupling protein (UCP) mRNA in the tissues: a study in spontaneously type 2 diabetic rats with visceral obesity.
Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Carrier Proteins; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Eating; Fatty Acids; Gene Expression Regulation; Hypolipidemic Agents; Insulin; Ion Channels; Leptin; Male; Membrane Proteins; Membrane Transport Proteins; Mitochondrial Proteins; Obesity; PPAR alpha; PPAR delta; Rats; Rats, Inbred Strains; RNA, Messenger; Thyroid Hormones; Uncoupling Agents; Uncoupling Protein 1; Uncoupling Protein 2; Uncoupling Protein 3; Viscera | 2004 |
The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.
Topics: Adipose Tissue; Animals; Bezafibrate; Body Composition; Body Weight; Diabetes Mellitus; Diet; Energy Metabolism; Glucose Clamp Technique; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Obesity; Organ Size; Oxazines; Pancreas; Phenylpropionates; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Rats, Inbred Strains; Receptors, Cell Surface; Receptors, Leptin; Thiazolidinediones | 2005 |
Risk reduction therapy for syndrome X: comparison of several treatments.
Topics: Amlodipine; Animals; Antihypertensive Agents; Bezafibrate; Blood Pressure; Body Weight; Captopril; Fructose; Hydrolases; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metabolic Syndrome; Rats; Rats, Sprague-Dawley; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Bezafibrate; Body Weight; Chromans; Colitis; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Female; Hypolipidemic Agents; Immunohistochemistry; Inflammation; Injections, Intraperitoneal; Ligands; Male; Mice; Mice, Inbred ICR; Nitric Oxide Synthase Type II; Organ Size; Peroxisome Proliferator-Activated Receptors; Sulfonamides; Temperature; Thiazolidinediones; Troglitazone; Tyrosine; Vasodilator Agents | 2005 |
The antihyperlipidemic activities of 4(3H) quinazolinone and two halogenated derivatives in rats.
Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Cholesterol, Dietary; Diabetes Mellitus, Experimental; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Malondialdehyde; Quinazolines; Quinazolinones; Rats | 2005 |
Bezafibrate improves bacterial lipopolysaccharide-induced dyslipidemia and anorexia in rats.
Topics: Animals; Anorexia; Bezafibrate; Blood Glucose; Blood Proteins; Blotting, Northern; Body Weight; Dyslipidemias; Energy Metabolism; Hypolipidemic Agents; Ion Channels; Lipopolysaccharides; Lipoprotein Lipase; Male; Mitochondrial Proteins; Muscle Proteins; Organ Size; Rats; Rats, Wistar; RNA, Messenger; Uncoupling Protein 3 | 2007 |
[Bezafibrate and delayed action etofibrate in hyperlipidemia].
Topics: Bezafibrate; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Humans; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Triglycerides | 1983 |
Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters.
Topics: Adult; Apolipoproteins; Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Esters; Fatty Acids; Female; Humans; Insulin; Lipids; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Triglycerides | 1980 |
[Effect of bezafibrate on the carbohydrate metabolism of 17 diabetics with hyperlipidemia].
Topics: Anticholesteremic Agents; Bezafibrate; Body Weight; Carbohydrate Metabolism; Clofibrate; Clofibric Acid; Diabetes Complications; Humans; Hyperlipidemias; Placebos | 1981 |
Clinical experience with bezafibrate.
Topics: Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Coronary Disease; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Male; Triglycerides | 1980 |
Contractility of the tail artery in rats treated with bezafibrate and fed atherogenic diet.
Topics: Administration, Oral; Animals; Bezafibrate; Body Weight; Calcium; Cholesterol; Diet, Atherogenic; Drug Administration Schedule; Drug Interactions; Male; Muscle Contraction; Muscle, Smooth, Vascular; Norepinephrine; Rats; Rats, Wistar | 1993 |
The effects of clofibrate and bezafibrate on cholesterol metabolism in the liver of the male rat.
Topics: Animals; Bezafibrate; Body Weight; Cholesterol; Cholesterol Esters; Clofibrate; Cytosol; Liver; Male; Microsomes, Liver; Rats; Rats, Wistar; Sterol Esterase; Sterol O-Acyltransferase | 1994 |
Transcriptional induction of the fatty acid binding protein gene in mouse liver by bezafibrate.
Topics: Animals; Bezafibrate; Blotting, Northern; Body Weight; Carrier Proteins; DNA Probes; Electrophoresis, Polyacrylamide Gel; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Gene Expression Regulation; Immunoblotting; Lipids; Liver; Male; Mice; Neoplasm Proteins; Nerve Tissue Proteins; Organ Size; RNA, Messenger; Transcription, Genetic | 1993 |
Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthase activity, and beta-oxidation in fructose-fed rats.
Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Chromans; Diet; Drug Tolerance; Fatty Acids, Nonesterified; Fructose; Glucose; Glycogen Synthase; Hypoglycemic Agents; Liver; Male; Mitochondria, Liver; Oxidation-Reduction; Potassium Cyanide; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1995 |
Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats.
Topics: Animals; Apolipoproteins B; Apolipoproteins E; Bezafibrate; Body Weight; Cholesterol; Cholesterol, LDL; Dose-Response Relationship, Drug; Gemfibrozil; Hypertriglyceridemia; Hypolipidemic Agents; Immunoelectrophoresis; Lipoprotein Lipase; Liver; Male; Rats; Rats, Sprague-Dawley; Spectrophotometry; Triglycerides | 1996 |
Uncoupling protein-3 mRNA levels are increased in white adipose tissue and skeletal muscle of bezafibrate-treated rats.
Topics: Adipose Tissue; Animals; Base Sequence; Bezafibrate; Body Weight; Carrier Proteins; Diabetes Mellitus, Type 2; DNA Primers; Hypolipidemic Agents; Insulin Resistance; Ion Channels; Leptin; Male; Mitochondria; Mitochondrial Proteins; Muscle, Skeletal; Organ Size; Proteins; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Uncoupling Protein 3 | 1999 |
Bezafibrate, an anti-hypertriglyceridemic drug, attenuates vascular hyperresponsiveness and elevated blood pressure in fructose-induced hypertensive rats.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Aorta; Bezafibrate; Blood Pressure; Body Weight; Calcium Channel Agonists; Dose-Response Relationship, Drug; Fructose; Hyperinsulinism; Hypertension; Hypertriglyceridemia; Hypolipidemic Agents; In Vitro Techniques; Lipoproteins, VLDL; Male; Rats; Rats, Sprague-Dawley; Vasoconstriction | 1999 |
Beneficial changes in serum apo A-1 and its ratio to apo B and HDL in stable hyperlipidaemic subjects after Ramadan fasting in Kuwait.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Bezafibrate; Body Weight; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Fasting; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Islam; Kuwait; Lipoproteins, HDL; Lovastatin; Male; Middle Aged | 2000 |
Bezafibrate induces acyl-CoA oxidase mRNA levels and fatty acid peroxisomal beta-oxidation in rat white adipose tissue.
Topics: Acyl-CoA Oxidase; Adipose Tissue; Animals; Bezafibrate; Body Weight; Cells, Cultured; Cholesterol; Fatty Acids; Hypolipidemic Agents; Leptin; Liver; Male; Oxidoreductases; Oxygen; Peroxisomes; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Temperature; Time Factors; Transcription Factors; Triglycerides | 2001 |
Involvement of calmodulin- and protein kinase C-related mechanism in an induction process of peroxisomal fatty acid oxidation-related enzymes by hypolipidemic peroxisome proliferators.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bezafibrate; Body Weight; Calmodulin; Catalase; Cells, Cultured; Clofibrate; Diethylhexyl Phthalate; Electrophoresis, Polyacrylamide Gel; Isoquinolines; Kinetics; Liver; Male; Membrane Proteins; Microbodies; Molecular Weight; Organ Size; Oxidation-Reduction; Piperazines; Protein Kinase C; Pyrimidines; Rats; Rats, Inbred Strains; Reference Values; Trifluoperazine | 1992 |